Knight Therapeutics (TSE:GUD) Shares Up 0.9% – Here’s Why

Shares of Knight Therapeutics Inc. (TSE:GUD) were up 0.9% during trading on Monday . The stock traded as high as C$9.87 and last traded at C$9.82. Approximately 52,009 shares were traded during trading, a decline of 47% from the average daily volume of 97,584 shares. The stock had previously closed at C$9.73.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$9.50 price target on shares of Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Price Performance

The stock has a market cap of C$964.12 million, a price-to-earnings ratio of 163.67, a P/E/G ratio of -1,013.50 and a beta of -0.21. The company has a 50 day simple moving average of C$9.24 and a 200-day simple moving average of C$7.63. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. The company had revenue of C$147.59 million during the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. Research analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.